Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 82, Issue 9, Pages 846-848Publisher
WILEY-LISS
DOI: 10.1002/ajh.20951
Keywords
-
Categories
Ask authors/readers for more resources
Rituximab is becoming popular as a treatment for immune thrombocytopenic purpura (ITP). We report here a patient with ITP, who initially responded to rituximab, but later became refractory. In this patient, the appearance of plasma cells producing anti-platelet autoantibodies is likely to be one of the mechanisms for rituximab resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available